Skip to main content
Advertisement
Global return-on-investment of COVID-19 vaccines in the first year of the vaccination programme: A model-based economic evaluation

November 5, 2026

Global return-on-investment of COVID-19 vaccines in the first year of the vaccination programme: A model-based economic evaluation

In this model-based economic evaluation, Hallie Benjamin and colleagues compare the costs of vaccine development, manufacturing, and delivery with estimated health and economic benefits during the first year of the COVID-19 vaccination program. The study reports estimated benefits far exceeding costs and highlights the potential importance of vaccine development and equitable distribution during global health emergencies.

Image credit: Maksim Goncharenok, Pexels

Recently Published Articles

Current Issue

Browse Issues 2004 – 2026

11/02/2026

Guidelines and Guidance

Addressing threats to validity in large dataset research

In this Guidelines and Guidance article, Wonsuk Yoo and John Ioannidis outline why research using large datasets faces threats to validity, highlighting four main statistical pitfalls and providing guidance and worked examples on how to mitigate against them.

Image credit: Mika Baumeister, Unsplash

Addressing threats to validity in large dataset research

11/03/2026

Research Article

Transforming pandemic influenza antiviral stockpiling using a capacity-based approach: A modeling study

In this modeling study, Nir Gavish and Amit Huppert examine whether traditional pandemic influenza antiviral stockpiles can keep hospital demand within available healthcare capacity during future pandemics. They find that while stockpiles may help in moderate outbreaks, they are unlikely to prevent severe capacity pressures in high-impact scenarios.

Image credit: Árpád Czapp, Unsplash

Transforming pandemic influenza antiviral stockpiling using a capacity-based approach: A modeling study

10/29/2026

Perspective

Pancreatic cancer: The RAS paradigm shift

Treatment approaches for pancreatic adenocarcinoma, an aggressive disease with poor prognosis, are evolving beyond cytotoxic chemotherapy. In this Perspective, Samuel Soff and Eileen O'Reilly discuss recent breakthroughs and clinical trial results of RAS-targeting small molecule inhibitors, as well as the challenges of treatment resistance.

Pancreatic cancer: The RAS paradigm shift

Image credit: Teslariu Mihai, Unsplash

PLOS Medicine | ISSN: 1549-1676 (online)